¼¼°èÀÇ ¼úÆù¾Æ¹Ìµå ½ÃÀå º¸°í¼­(2025³â)
Sulfonamide Global Market Report 2025
»óǰÄÚµå : 1760725
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼³Æù¾Æ¹Ìµå ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö ¿¬Æò±Õ 6.8%ÀÇ ¼ºÀå·ü·Î 37¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº º´¿ë¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Ç×±ÕÁ¦ ³»¼º °ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡, °³¹ßµµ»ó±¹ÀÇ ÀÇ·á Á¢±Ù¼º È®´ë, ³ó¾÷ ¹× Ãà»ê¾÷ ºÐ¾ß¿¡¼­ÀÇ »ç¿ë È®´ë, ¼³Æù¾Æ¹Ìµå Á¦Á¦¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ÁöÁöÀû ½ÂÀÎ µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¾à¹° Àü´Þ ±â¼úÀÇ ¹ßÀü, ¼³Æù¾Æ¹Ìµå À¯µµÃ¼ÀÇ Çõ½Å, Ç¥Àû Ç×±Õ ¿ä¹ýÀÇ °³¹ß, Ç×±ÕÁ¦ÀÇ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß, ½Å¾à °³¹ß¿¡ ÀΰøÁö´ÉÀÇ ÅëÇÕ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

ÇǺΠ°¨¿°ÀÇ È®»êÀº ¼³Æù¾Æ¹Ìµå ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇǺΠ°¨¿°Àº ÇǺο¡ ħÀÔÇÑ ¼¼±Õ, ¹ÙÀÌ·¯½º, Áø±Õ, °õÆÎÀÌ, ±â»ýÃæ¿¡ ÀÇÇØ ¹ß»ýÇÏ¸ç ¹ßÀû, ºÎÁ¾, ÅëÁõ, °¡·Á¿òÁõ, È­³ó µîÀÇ Áõ»óÀ» À¯¹ßÇÕ´Ï´Ù. ÇǺΠ°¨¿°Áõ Áõ°¡´Â Ç×»ýÁ¦ ³»¼º±Õ Áõ°¡¿¡ ±âÀÎÇÏ´Â ¹Ù°¡ Å©¸ç, ÀϹÝÀûÀÎ °¨¿°Àº Ä¡·á°¡ ¾î·Æ°í È®»êµÇ±â ½±½À´Ï´Ù. ¼³Æù¾Æ¹Ìµå´Â ¹ÚÅ׸®¾ÆÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ°í ¿±»êÀÇ ÇÕ¼ºÀ» ¾ïÁ¦ÇÏ¿© ´Ù¾çÇÑ °¨¼ö¼º ¹ÚÅ׸®¾Æ¿¡ È¿°úÀûÀ̸ç, ÇǺΠ°¨¿° Ä¡·á¿¡ È¿°úÀûÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 2¿ù ¹Ì±¹ ºñ¿µ¸®´ÜüÀÎ ¹Ì±¹ÇǺΰúÇÐȸ´Â ¸Å³â ¾à 5,000¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¿©µå¸§À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ´Â ¹Ì±¹¿¡¼­ °¡Àå ÈçÇÑ ÇǺΠÁúȯÀ̶ó°í º¸°íÇß½À´Ï´Ù. ±× °á°ú, ÇǺΠ°¨¿°ÀÇ À¯º´·ü Áõ°¡´Â ¼³Æù¾Æ¹Ìµå ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¼³Æù¾Æ¹Ìµå ½ÃÀåÀÇ ±â¾÷µéÀº ¼³Æù¾Æ¹Ìµå ±â¹Ý ¾à¹°ÀÇ Ä¡·á ¿ëµµ¸¦ È®ÀåÇϰí, Èñ±Í ½Å°æ±Ù ÁúȯÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ¿ø¹ß¼º Áֱ⼺ ¸¶ºñ(PPP)¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ±ÙÀ° ¾àÈ­ ¹× ¸¶ºñ ¿¡ÇǼҵ带 À¯¹ßÇÏ´Â Èñ±Í À¯Àü¼º ½Å°æ±ÙÀ° Áúȯ±ºÀ» °ü¸®Çϱâ À§ÇÑ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù ¿µ±¹¿¡ º»»ç¸¦ µÐ Á¦¾à»ç »çÀÌŬ ÆÄ¸¶½´Æ¼Äýº(Cycle Pharmaceuticals Limited)´Â ÀúÄ®·ýÇ÷Áõ¼º Áֱ⼺ ¸¶ºñ(HypoPP), °íÄ®·ýÇ÷Áõ¼º Áֱ⼺ ¸¶ºñ(HyperPP) ¹× À¯»ç Áúȯ ȯÀÚ¸¦ À§ÇÑ Ä¡·á ¿É¼ÇÀ¸·Î ORMALVITM(µðŬ·Î¸£Æä³ª¹Ìµå)À» ¹ßÇ¥Çß½À´Ï´Ù. µðŬ·Î¸£Æä³ª¹Ìµå)¸¦ ¹ßÇ¥Çß½À´Ï´Ù. FDA ½ÂÀÎÀ» ¹ÞÀº ÀÌ Ä¡·áÁ¦´Â Ä®·ý ³óµµ º¯µ¿°ú °ü·ÃµÈ ±ÙÀ° ¾àÈ­ ¹× ¸¶ºñ¸¦ Ư¡À¸·Î ÇÏ´Â ÀÌ À¯Àü¼º Áúȯ¿¡ ƯȭµÈ Ä¡·áÁ¦¸¦ Á¦°øÇÕ´Ï´Ù. À̹ø Ãâ½Ã¿¡¼­ ÁÖ¸ñÇÒ ¸¸ÇÑ Á¡Àº ȯÀÚ Áß½ÉÀÇ Á¢±Ù ¹æ½Ä°ú ¸ÂÃãÇü Áö¿ø ¼­ºñ½º¸¦ ÅëÇØ Á¢±Ù¼º°ú ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í ÄڷγªÀç³­°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Sulfonamide refers to a group of synthetic antimicrobial agents containing the sulfonamide group, used to treat bacterial infections by inhibiting folic acid synthesis in microbes. These compounds were among the earliest antibiotics developed and remain in use today as part of combination therapies for various infections.

The main product types of sulfonamide include oral sulfonamides, topical sulfonamides, and injectable sulfonamides. Oral sulfonamides are antibiotics that contain the sulfonamide group (-SO2NH2) in their chemical structure. The key chemical structures include sulfanilamide, sulfacetamide, and sulfamethoxazole. Applications include antibacterial, antifungal, antiviral, diuretics, antidiabetic, and others, and they are used by various end users such as hospitals, clinics, research laboratories, and others.

The sulfonamide market research report is one of a series of new reports from The Business Research Company that provides sulfonamide market statistics, including the sulfonamide industry global market size, regional shares, competitors with the sulfonamide market share, detailed sulfonamide market segments, market trends, and opportunities, and any further data you may need to thrive in the sulfonamide industry. This sulfonamide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sulfonamide market size has grown strongly in recent years. It will grow from $2.72 billion in 2024 to $2.91 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the increasing prevalence of bacterial infections, growing availability of generic sulfonamide drugs, rising cost-effective treatment options, expanded use in veterinary medicine, and the expanding pharmaceutical manufacturing capacity.

The sulfonamide market size is expected to see strong growth in the next few years. It will grow to $3.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising demand for combination therapies, increasing focus on antimicrobial resistance management, expansion of healthcare access in developing regions, growing applications in agriculture and animal husbandry, and supportive regulatory approvals for sulfonamide formulations. Major trends in the forecast period include advancements in drug delivery technologies, innovations in sulfonamide derivatives, development of targeted antibacterial therapies, ongoing research and development in antimicrobial agents, and integration of artificial intelligence in drug discovery.

The growing prevalence of skin infections is expected to drive the expansion of the sulfonamide market. Skin infections, caused by bacteria, viruses, fungi, or parasites invading the skin, lead to symptoms such as redness, swelling, pain, itching, or pus formation. The rise in skin infections is largely due to the increasing presence of antibiotic-resistant bacteria, making common infections more difficult to treat and more likely to spread. Sulfonamides are effective in treating skin infections by inhibiting bacterial growth and disrupting folic acid synthesis, making them effective against various susceptible bacteria. For example, in February 2025, the American Academy of Dermatology, a U.S.-based nonprofit organization, reported that approximately 50 million Americans suffer from acne each year, making it the most common skin condition in the country. As a result, the increasing prevalence of skin infections is fueling the growth of the sulfonamide market.

Companies in the sulfonamide market are focusing on developing innovative therapies, such as those for primary periodic paralysis (PPP), to expand the therapeutic applications of sulfonamide-based drugs and address unmet needs in rare neuromuscular disorders. PPP therapies are designed to manage a group of rare, inherited neuromuscular disorders that cause episodes of muscle weakness or paralysis triggered by changes in blood potassium levels. For example, in May 2024, Cycle Pharmaceuticals Limited, a U.K.-based pharmaceutical company, introduced ORMALVITM (dichlorphenamide) as a therapy option for patients with hypokalemic periodic paralysis (HypoPP), hyperkalemic periodic paralysis (HyperPP), and similar conditions. This FDA-approved therapy provides a specialized treatment for these genetic disorders, characterized by muscle weakness or paralysis linked to fluctuations in potassium levels. A notable feature of this launch is Cycle's patient-centric approach, which focuses on improving accessibility and adherence through tailored support services.

In June 2023, Shionogi & Company Limited, a Japan-based pharmaceutical company, merged with Qpex Biopharma Inc. to accelerate antibiotic research and development, addressing the growing issue of antimicrobial resistance (AMR). This merger allows Shionogi to enhance its expertise in antibiotic research and AMR by combining its strengths with Qpex Biopharma's innovative compounds and networks, speeding up the development of vital pharmaceuticals. Qpex Biopharma Inc. is a U.S.-based company focused on creating novel anti-infective therapies, particularly those targeting drug-resistant infections.

Major players in the sulfonamide market are Abbott Laboratories, Novartis AG, Teva Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Lupin Limited, Bimeda Holdings PLC, Fera Science Limited, Virchow Laboratories Limited, Hebei Veyong Bio-Chemical Co. Ltd., Interchemie Werken De Adelaar B.V., AdvaCare Pharma, Manus Aktteva Biopharma LLP, Suleshvari Pharma, Shree Vardayini Chemical Industries Private Limited, VetOne, Zydus Cadila Healthcare Limited, Mission Pharmacal Company, Allegis Pharmaceuticals LLC.

North America was the largest region in the sulfonamide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sulfonamide report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sulfonamide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sulfonamide market consists of sales of sulfamethoxazole, sulfadiazine, furosemide, and thiazide diuretics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sulfonamide Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sulfonamide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for sulfonamide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sulfonamide market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Sulfonamide Market Characteristics

3. Sulfonamide Market Trends And Strategies

4. Sulfonamide Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sulfonamide Growth Analysis And Strategic Analysis Framework

6. Sulfonamide Market Segmentation

7. Sulfonamide Market Regional And Country Analysis

8. Asia-Pacific Sulfonamide Market

9. China Sulfonamide Market

10. India Sulfonamide Market

11. Japan Sulfonamide Market

12. Australia Sulfonamide Market

13. Indonesia Sulfonamide Market

14. South Korea Sulfonamide Market

15. Western Europe Sulfonamide Market

16. UK Sulfonamide Market

17. Germany Sulfonamide Market

18. France Sulfonamide Market

19. Italy Sulfonamide Market

20. Spain Sulfonamide Market

21. Eastern Europe Sulfonamide Market

22. Russia Sulfonamide Market

23. North America Sulfonamide Market

24. USA Sulfonamide Market

25. Canada Sulfonamide Market

26. South America Sulfonamide Market

27. Brazil Sulfonamide Market

28. Middle East Sulfonamide Market

29. Africa Sulfonamide Market

30. Sulfonamide Market Competitive Landscape And Company Profiles

31. Sulfonamide Market Other Major And Innovative Companies

32. Global Sulfonamide Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sulfonamide Market

34. Recent Developments In The Sulfonamide Market

35. Sulfonamide Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â